Dihydroresveratrol|CAS 58436-28-5|DC Chemicals

Cas No.:	58436-28-5
Chemical Name:	Dihydroresveratrol
Synonyms:	5--2--4-Hydroxyphenyl-ethyl-benzene-1-3-diol;Dihydroresveratrol;5-[2-(4-hydroxyphenyl)ethyl]-1,3-Benzenediol;5-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diol;3,4',5-Trihydroxybibenzyl;3',4,5'-trihydroxydihydrostilbene;3,5,4'-trihydroxybibenzyl;3ftu;dihydroresverantrol;Dihydro-Resveratrol;RE2;[ "" ];5-(4-hydroxyphenethyl)benzene-1,3-diol;Dihydroresveratol;a, b-Dihydroresveratrol;C10255;alpha,beta-Dihydroresveratrol;3,4'',5-trihydroxybibenzyl;1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethyl)-;NSC723534;151363-17-6;DTXSID60973983;DB08466;HY-N3755;CS-0024161;5-(2-(4-HYDROXYPHENYL)ETHYL)BENZENE-1,3-DIOL;58436-28-5;NSC-723534;ButanaMide, 4-aMino-N-ethyl-, Monohydrochloride;BS-17153;UNII-CBY43AY0TT;FT-0756540;5-[2-(4-Hydroxy-phenyl)-ethyl]-benzene-1,3-diol;s6927;SCHEMBL716856;SY232649;NS00068421;Q5276414;CBY43AY0TT;alpha,beta-dihydro-3,40,5-trihydroxystilbene;CHEMBL111234;LMPK13090035;CHEBI:4582;MFCD25973128;BDBM50085531;AKOS030555676;4-(2-(3,5-Dihydroxyphenyl)ethyl)phenol;3,5,4'-Trihydroxybibenzyl;ConMedNP.2938;3_4'_5-Trihydroxybibenzyl;3,4',5-trihydroxybibenzyl
SMILES:	O([H])C1C([H])=C(C([H])=C(C=1[H])C([H])([H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])O[H]
Formula:	C₁₄H₁₄O₃
M.Wt:	230.2592
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.